TY - JOUR
T1 - Systematic Review of Diagnostic Criteria Used in Atopic Dermatitis Randomized Controlled Trials
AU - Vakharia, Paras P.
AU - Chopra, Rishi
AU - Silverberg, Jonathan I.
N1 - Funding Information:
Funding This publication was made possible with support from the Agency for Healthcare Research and Quality, Grant No. K12 HS023011, and the Dermatology Foundation.
Funding Information:
The authors thank Yufan Yan, BS, Northwestern University Feinberg School of Medicine for providing assistance with translation services. This publication was made possible with support from the Agency for Healthcare Research and Quality, Grant No. K12 HS023011, and the Dermatology Foundation. Jonathan I. Silverberg, Paras P. Vakharia, and Rishi Chopra have no conflicts of interest directly relevant to the contents of this study.
Publisher Copyright:
© 2017, Springer International Publishing Switzerland.
PY - 2018/2/1
Y1 - 2018/2/1
N2 - Background: Numerous diagnostic criteria for atopic dermatitis are used in clinical trials, which may limit comparison of results. Objective: We sought to determine the most commonly used atopic dermatitis diagnostic criteria in randomized controlled trials internationally. Methods: We performed a systematic review of randomized controlled trials with a pharmacological intervention from 2007 to 2016. Cochrane Library, EMBASE, GREAT, LILACS, MEDLINE, and Scopus were searched. Two authors independently performed the study selection and data extraction. Results: Two hundred and twelve randomized controlled trials met inclusion/exclusion criteria. Overall, ten different diagnostic criteria were used. The Hanifin and Rajka criteria were most commonly used (41.0%), followed by the UK refinement of the Hanifin and Rajka criteria (9.0%), Japanese Dermatological Association criteria (4.2%), and American Academy of Dermatology criteria (3.8%). No diagnostic criteria were specified in 37.3% of randomized controlled trials. The Hanifin and Rajka criteria were the most commonly used atopic dermatitis diagnostic criteria in clinical trials of topical and systemic interventions, across all years between 2007 and 2016, in pediatric and adult populations, in most countries and regions internationally. Conclusions: The results highlight the lack of uniformity and documentation of atopic dermatitis diagnostic criteria in randomized controlled trials for atopic dermatitis. We recommend harmonizing the diagnostic criteria for atopic dermatitis in future randomized controlled trials.
AB - Background: Numerous diagnostic criteria for atopic dermatitis are used in clinical trials, which may limit comparison of results. Objective: We sought to determine the most commonly used atopic dermatitis diagnostic criteria in randomized controlled trials internationally. Methods: We performed a systematic review of randomized controlled trials with a pharmacological intervention from 2007 to 2016. Cochrane Library, EMBASE, GREAT, LILACS, MEDLINE, and Scopus were searched. Two authors independently performed the study selection and data extraction. Results: Two hundred and twelve randomized controlled trials met inclusion/exclusion criteria. Overall, ten different diagnostic criteria were used. The Hanifin and Rajka criteria were most commonly used (41.0%), followed by the UK refinement of the Hanifin and Rajka criteria (9.0%), Japanese Dermatological Association criteria (4.2%), and American Academy of Dermatology criteria (3.8%). No diagnostic criteria were specified in 37.3% of randomized controlled trials. The Hanifin and Rajka criteria were the most commonly used atopic dermatitis diagnostic criteria in clinical trials of topical and systemic interventions, across all years between 2007 and 2016, in pediatric and adult populations, in most countries and regions internationally. Conclusions: The results highlight the lack of uniformity and documentation of atopic dermatitis diagnostic criteria in randomized controlled trials for atopic dermatitis. We recommend harmonizing the diagnostic criteria for atopic dermatitis in future randomized controlled trials.
UR - http://www.scopus.com/inward/record.url?scp=85041459195&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85041459195&partnerID=8YFLogxK
U2 - 10.1007/s40257-017-0299-4
DO - 10.1007/s40257-017-0299-4
M3 - Review article
C2 - 28624959
AN - SCOPUS:85041459195
VL - 19
SP - 15
EP - 22
JO - American Journal of Clinical Dermatology
JF - American Journal of Clinical Dermatology
SN - 1175-0561
IS - 1
ER -